CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 247 enrolled
Drug / intervention
MR13A9 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03802617
NCT03802617Phase 2Completed
CompareCT.gov

A Phase II Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Jan 14, 2019·Updated Dec 5, 2025

In Brief

A Phase 2 clinical trial evaluating MR13A9 and Placebo for Uremic Pruritus. Completed, enrolled 247 participants across 1 site.

Detailed Summary

Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUremic Pruritus
CountriesJapan
CollaboratorsMaruishi Pharmaceutical

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 14, 2019
Enrollment StartFeb 1, 2019
Primary CompletionOct 22, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.5 years ago

Interventions

MR13A9drug

Intravenous administration

Placebodrug

Intravenous administration